Home › Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab
 

Keywords :   


Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab

2014-09-23 07:04:12| Biotech - Topix.net

THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen today announced submission of a Biologics License Application to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager antibody construct, blinatumomab.

Tags: bla submits investigational immunotherapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »